Clinical Trials Sponsored by Bavarian Nordic GmbH

Total 84 results

Bavarian Nordic

Recruiting

Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination

Chikungunya Virus Infection

United States
Bavarian Nordic

Completed

A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer

Solid Metastatic Tumor

United States
Bavarian Nordic

Completed

A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects

Smallpox

United States
Bavarian Nordic

Completed

Special Access Program IMVAMUNE®

Vaccination

United States
Bavarian Nordic

Completed

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer (Prospect)

Prostate Cancer Metastatic

United States, Spain, Germany, Netherlands, Belgium, United Kingdom, Australia, Denmark, France, Canada, Israel, Russian Federation, Puerto Rico, Estonia, Poland, Iceland
Bavarian Nordic

Completed

A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer

Breast Cancer

United States
Bavarian Nordic

Withdrawn

RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.

Respiratory Syncytial Virus Infections
Bavarian Nordic

Completed

Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine

Respiratory Syncytial Virus Infections

United States
Bavarian Nordic

Completed

Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected Subjects

HIV Infections

United States
Bavarian Nordic

Completed

Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects

Smallpox

Germany
Bavarian Nordic

Completed

Study on Safety, Tolerability and Immunogenicity of an MVA Vaccine Administered to Healthy Subjects

Smallpox

Germany
Bavarian Nordic

Completed

Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults

RSV Infection

United Kingdom
Bavarian Nordic

Active, not recruiting

ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects

COVID-19 Disease

Germany
Bavarian Nordic

Completed

RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults

Respiratory Syncytial Virus Infections

United States
Bavarian Nordic

Completed

Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection

Smallpox

United States, Puerto Rico
Bavarian Nordic

Completed

A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects

Smallpox

United States
Bavarian Nordic

Active, not recruiting

TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer

Chordoma | HER2-positive Breast Cancer | HER2-positive Gastric/Gastroesophageal Junction Cancer

United States
Bavarian Nordic

Completed

ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

COVID-19 Disease

United States, Denmark, Belgium
Bavarian Nordic

Completed

MVA-BN-RSV Vaccine Trial

Respiratory Syncytial Virus Infections

United States, Germany
Bavarian Nordic

Completed

BN Brachyury and Radiation in Chordoma

Chordoma

United States
Bavarian Nordic

Completed

CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

Bladder Cancer

United States
Bavarian Nordic

Completed

Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury)

Safety Issues

United States
Bavarian Nordic

Completed

A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

United States
Bavarian Nordic

Completed

A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy

Breast Cancer

United States
Bavarian Nordic

Completed

A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer (BNIT-PR-001)

Androgen-insensitive Prostate Cancer

United States
Bavarian Nordic

Completed

A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

Smallpox

United States
Bavarian Nordic

Completed

Safety and Immunogenicity Study of Recombinant Modified Vaccinia Virus Ankara (MVA) Virus to Treat HIV Infection

HIV Infections

Germany
Bavarian Nordic

Completed

Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years

Measles

South Africa
Janssen Vaccines & Prevention B.V.
Bavarian Nordic GmbH

Terminated

Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo

Hemorrhagic Fever, Ebola

France, United Kingdom, Kenya, United States, Uganda, Burkina Faso, Tanzania
Bavarian Nordic
Emergent BioSolutions

Completed

A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317

Chikungunya Virus

United States
Bavarian Nordic
Emergent BioSolutions

Completed

A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults

Cholera

United States, Australia
Bavarian Nordic
Emergent BioSolutions

Completed

Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers

Typhoid Fever

United States
Bavarian Nordic
Emergent BioSolutions

Completed

A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine (CHIKV VLP)

Chikungunya Virus

United States
Bavarian Nordic
Emergent BioSolutions

Completed

A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults

Cholera

United States
Bavarian Nordic
Emergent BioSolutions

Completed

VAXCHORA Pediatric Study to Assess Safety and Immunogenicity

Cholera (Disorder)

United States
Bavarian Nordic
Emergent BioSolutions

Completed

Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200

Cholera

United States
Bavarian Nordic
Emergent BioSolutions

Completed

Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults

Chikungunya Virus Infection

United States
Bavarian Nordic
Emergent BioSolutions

Completed

Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera

Cholera

United States
Bavarian Nordic
JPM CBRN Medical

Completed

Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects

Equine Encephalitis

United States
Public Health England
Bavarian Nordic

Completed

Cohort Study of Healthcare Workers Receiving Imvanex®

Monkeypox

United Kingdom
Janssen Vaccines & Prevention B.V.
Bavarian Nordic

Terminated

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

Human Papillomavirus Infections

United States, Belgium
University of Utah
Genentech, Inc.; Bavarian Nordic

Withdrawn

Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer (AtezoVax)

Prostate Adenocarcinoma

United States
Bavarian Nordic
National Institutes of Health (NIH)

Completed

An Evaluation of Immunogenicity and Safety of Two Doses of MVA-nef vs. MVA-BN in HIV-1 Infected Patients

HIV Infection

Germany
Bavarian Nordic
National Institutes of Health (NIH)

Completed

Single-Blind, Controlled Safety and Immunogenicity Study of Recombinant MVA Virus to Treat HIV Infection

HIV Infections

Germany
Medical University of South Carolina
Bavarian Nordic

Active, not recruiting

Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy

Prostatic Neoplasms

United States
Bavarian Nordic
National Institutes of Health (NIH)

Completed

Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients

HIV Infections

United States, Puerto Rico
Bavarian Nordic
Biomedical Advanced Research and Development Authority

Completed

Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial

Smallpox

United States
Bavarian Nordic
Emergent BioSolutions; Catalyst Clinical Research, LLC

Completed

Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years

Chikungunya Virus

United States
Bavarian Nordic
National Cancer Institute (NCI); Therion Biologics Corporation

Completed

PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy

Prostate Cancer

United States
Lawrence Fong
Bavarian Nordic

Terminated

Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer

Prostatic Neoplasms

United States

3

Subscribe